CIK 0000887359
- Large accelerated filer
Vericel Corp
Sign in to watch- Ticker
- VCEL
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- MI
- Entity type
- Operating
- EIN
- 943096597
- Phone
- +1 617-588-5555
- Business address
- 25 BLUE SKY DRIVE, BURLINGTON, MA, 01803
- Former names
- AASTROM BIOSCIENCES INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $5,896,581
- in 8 filings, $5.8M under 10b5-1 plans
Net −$5,896,581. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Mara Joseph Anthony Jr −$4.1M Chief Financial Officer sold 82% of stake
- Flynn Sean C. −$779K Chief Legal Officer sold 88% of stake
- MCLAUGHLIN KEVIN F −$413K Director sold 28% of stake
- ZERBE ROBERT L MD −$386K Director sold 19% of stake
- SIEGAL JONATHAN −$188K Principal Accounting Officer sold 73% of stake
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-01-29 | ZERBE ROBERT L MD Director | Sale | −2,300 | $44.22 | $102K | 23,395 |
| 2024-01-25 | ZERBE ROBERT L MD Director | Sale 10b5-1 | −200 | $44.02 | $9K | 25,695 |
| 2024-01-22 | ZERBE ROBERT L MD Director | Sale 10b5-1 | −2,500 | $41.39 | $103K | 28,395 |
| 2024-01-22 | ZERBE ROBERT L MD Director | Sale 10b5-1 | −2,500 | $42.06 | $105K | 25,895 |
| 2024-01-22 | ZERBE ROBERT L MD Director | Sale 10b5-1 | −3,000 | $42.05 | $126K | 25,895 |
| 2024-01-18 | Colangelo Dominick President and CEO | Sale 10b5-1 | −16,726 | $38.58 | $645K | 169,985 |
| 2024-01-17 | Colangelo Dominick President and CEO | Sale 10b5-1 | −16,726 | $37.97 | $635K | 169,985 |
| 2024-01-12 | ZERBE ROBERT L MD Director | Sale 10b5-1 | −2,200 | $38.09 | $84K | 30,895 |
| 2023-12-14 | Flynn Sean C. SVP, General Counsel | Sale | −106 | $37.45 | $4K | 4,467 |
| 2023-12-14 | Wotton Paul K Director | Sale | −5,000 | $37.31 | $187K | 26,802 |
| 2023-12-14 | Colangelo Dominick President and CEO | Sale 10b5-1 | −12,000 | $37.12 | $445K | 169,985 |
| 2023-12-13 | Flynn Sean C. SVP, General Counsel | Sale | −1,432 | $34.20 | $49K | 4,573 |
| 2023-12-13 | Colangelo Dominick President and CEO | Sale 10b5-1 | −12,000 | $34.03 | $408K | 169,985 |
| 2023-12-07 | Colangelo Dominick President and CEO | Sale 10b5-1 | −12,000 | $33.84 | $406K | 176,742 |
| 2023-12-06 | Colangelo Dominick President and CEO | Sale 10b5-1 | −12,397 | $34.43 | $427K | 176,742 |
| 2023-11-30 | Halpin Michael Chief Operating Officer | Sale 10b5-1 | −17,447 | $35.41 | $618K | 827 |
| 2023-11-20 | Hopper Jonathan Mark Chief Medical Officer | Sale 10b5-1 | −5,000 | $36.40 | $182K | 53,007 |
| 2023-11-15 | ZERBE ROBERT L MD Director | Sale 10b5-1 | −200 | $38.00 | $8K | 33,195 |
| 2023-11-15 | ZERBE ROBERT L MD Director | Sale 10b5-1 | −100 | $38.06 | $4K | 33,095 |
| 2023-11-15 | SIEGAL JONATHAN Principal Accounting Officer | Sale | −662 | $37.70 | $25K | 1,305 |
Page 7 of 14 · 279 trades